Patents Assigned to Immunex
  • Methods of treating inflammation using IL-17 antagonists
    Publication number: 20090274703
    Abstract: Aspects of the present invention provide methods for treating diseases associated with IL-17 mediated inflammatory or immunoregulatory reactions.
    Type: Application
    Filed: January 29, 2009
    Publication date: November 5, 2009
    Applicant: Immunex Corporation
    Inventor: Kendall M. Mohler
  • UL16 BINDING PROTEIN 4
    Publication number: 20090274699
    Abstract: ULBP4, a novel member of the ULBP family has been isolated and characterized. ULBP4 is a useful activator of immune effector cells, particularly of NK cells.
    Type: Application
    Filed: June 5, 2009
    Publication date: November 5, 2009
    Applicant: Immunex Corporation
    Inventor: David J. Cosman
  • CD30 Ligand
    Publication number: 20090264349
    Abstract: There is disclosed a polypeptide (CD30-L) and DNA sequences, vectors and transformed host cells useful in providing CD30-L polypeptides. The CD30-L polypeptide binds to the receptor known as CD30, which is expressed on a number of cell types, among which are Hodgkin's Disease tumor cells, large cell anaplastic lymphoma cells, adult T-cell leukemia (T-ALL) cells, and a number of other malignant cell types. CD30-L polypeptides find use as carriers for delivering diagnostic and cytotoxic agents to cells expressing the CD30 receptor.
    Type: Application
    Filed: May 9, 2007
    Publication date: October 22, 2009
    Applicant: Immunex Corporation
    Inventors: Raymond G. Goodwin, Craig A. Smith, Richard J. Armitage, Hans-Juergen Gruss
  • Treating diseases mediated by metalloprotease-shed proteins
    Publication number: 20090247605
    Abstract: This invention relates to the identification of membrane-associated proteins shed by metalloproteinases and in particular by TNF-alpha converting enzyme (TACE), to the use of such metalloproteinase-shed proteins in assays for TACE agonists and antagonists, and to the use of metalloproteinase agonists and antagonists, and particularly TACE agonists and antagonists, in the treatment of diseases mediated by certain shed proteins.
    Type: Application
    Filed: June 28, 2007
    Publication date: October 1, 2009
    Applicant: Immunex Corporation
    Inventors: Richard S. Johnson, Lin Guo, Jacques J. Peschon, Roy A. Black, Rajeev M. Mahimkar
  • IL-1 ETA DNA AND POLYPEPTIDES
    Publication number: 20090232816
    Abstract: The invention is directed to novel purified and isolated IL-1 eta polypeptides and fragment thereof, the polynucleotides encoding such, polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, peptides derived from these polypeptides, and uses thereof.
    Type: Application
    Filed: May 24, 2007
    Publication date: September 17, 2009
    Applicant: IMMUNEX CORPORATION
    Inventors: JOHN E. SIMS, BLAIR R. RENSHAW
  • Human OX2 receptors
    Patent number: 7589175
    Abstract: Isolated receptors, nucleic acids encoding such receptors, and pharmaceutical compositions made therefrom, are disclosed. The isolated receptors can be used to regulate an immune response. The receptors are also useful in screening for inhibitors or agonists thereof.
    Type: Grant
    Filed: January 30, 2007
    Date of Patent: September 15, 2009
    Assignee: Immunex Corporation
    Inventors: Anne-Reńee Van Der Vuurst De Vries, Laurent J. Galibert
  • Human B7 polypeptides
    Publication number: 20090226417
    Abstract: This invention relates to B7-H1.2 and Butryophilin 2/3, new members of the human B7 polypeptide family, methods of making such polypeptides, and to methods of using them to treat immunological conditions and to identify compounds that alter the activities of these human B7 polypeptides.
    Type: Application
    Filed: August 8, 2007
    Publication date: September 10, 2009
    Applicant: Immunex Corporation
    Inventors: Peter R. Baum, Robert F. DuBose, Steven R. Wiley
  • IL-1 zeta splice variant polypeptide
    Patent number: 7585949
    Abstract: The invention is directed to novel, purified and isolated IL-1 zeta and Xrec2 polypeptides and fragments thereof, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and uses thereof.
    Type: Grant
    Filed: March 13, 2007
    Date of Patent: September 8, 2009
    Assignee: Immunex Corporation
    Inventors: John E. Sims, Dirk E. Smith, Teresa L. Born
  • Screening assays for agonists or antagonists or receptor activator of NF-?B
    Patent number: 7572594
    Abstract: The present invention provides methods for screening for a molecule that antagonizes or agonizes RANK activity. One aspect of the invention involves the growth of RANK responsive cells in semi-solid medium, wherein exposure to a RANK antagonist promotes colony formation. Other aspects of the invention rely on promoter/reporter constructs using RANK responsive promoters derived from the MMP-9 and TRAP genes. Additional aspects of the invention exploit the ability of RANK to activate c-src activity, F-actin ring formation and CaPO4 resorption.
    Type: Grant
    Filed: April 4, 2005
    Date of Patent: August 11, 2009
    Assignee: Immunex Corporation
    Inventor: William C. Dougall
  • UL16 binding protein 4
    Patent number: 7563450
    Abstract: ULBP4, a novel member of the ULBP family has been isolated and characterized. ULBP4 is a useful activator of immune effector cells, particularly of NK cells.
    Type: Grant
    Filed: October 4, 2002
    Date of Patent: July 21, 2009
    Assignee: Immunex Corporation
    Inventor: David J. Cosman
  • SOLUBLE TUMOR NECROSIS FACTOR RECEPTOR TREATMENT OF MEDICAL DISORDERS
    Publication number: 20090163424
    Abstract: The invention pertains to methods and compositions for treating medical disorders characterized by elevated levels or abnormal expression of TNF? by administering a TNF? antagonist, such as recombinant TNFR:Fc.
    Type: Application
    Filed: February 27, 2009
    Publication date: June 25, 2009
    Applicant: IMMUNEX CORPORATION
    Inventors: Barbara K. FINCK, Larry O'Neal, John D. Pluenneke, Timothy Connor
  • Molecules designated LDCAM
    Publication number: 20090155845
    Abstract: The invention is directed to LDCAM as a purified and isolated protein, the DNA encoding the LDCAM, host cells transfected with cDNAs encoding LDCAM, processes for preparing LDCAM polypeptides and compositions and methods for treating utilizing LDCAM polypeptides.
    Type: Application
    Filed: July 14, 2008
    Publication date: June 18, 2009
    Applicant: Immunex Corporation
    Inventors: Peter Robert Baum, William Christian Fanslow, III
  • Increased recovery of active proteins
    Patent number: 7544784
    Abstract: The invention provides methods of increasing yields of desired conformation of proteins. In particular embodiments, the invention includes contacting preparations of a recombinant protein with a reduction/oxidation coupling reagent for a time sufficient to increase the relative proportion of a desired configurational isomer.
    Type: Grant
    Filed: November 22, 2006
    Date of Patent: June 9, 2009
    Assignee: Immunex Corporation
    Inventors: Helmut M. Sassenfeld, Richard L. Remmele, Jr., Rebecca E. McCoy
  • BTL-II NUCLEIC ACIDS
    Publication number: 20090142801
    Abstract: The invention provides isolated BTL-II proteins, nucleic acids, antibodies, antagonists, and agonists and methods of making and using the same. Diagnostic, screening, and therapeutic methods using the compositions of the invention are provided. For example, the compositions of the invention can be used for diagnosis and treatment of inflammatory bowel diseases and for enhancing a mucosal immune response to an antigen.
    Type: Application
    Filed: June 8, 2007
    Publication date: June 4, 2009
    Applicant: IMMUNEX CORPORATION
    Inventors: Peter R. BAUM, Sabine S. ESCOBAR, Joanne L. VINEY
  • Methods for treating rheumatoid arthritis using IL-17 antagonists
    Publication number: 20090130122
    Abstract: A method of treating a mammal afflicted with rheumatoid arthritis comprising administering a soluble form of IL-17 receptor is disclosed.
    Type: Application
    Filed: February 22, 2008
    Publication date: May 21, 2009
    Applicant: Immunex Corporation
    Inventor: Kendall M. Mohler
  • Use of TRAIL Polypeptides to Treat Cancer
    Publication number: 20090118186
    Abstract: A novel cytokine designated TRAIL induces apoptosis of certain target cells, including cancer cells and virally infected cells. Isolated DNA sequences encoding TRAIL are disclosed, along with expression vectors and transformed host cells useful in producing TRAIL polypeptides. Antibodies that specifically bind TRAIL are provided as well.
    Type: Application
    Filed: August 21, 2008
    Publication date: May 7, 2009
    Applicant: IMMUNEX CORPORATION
    Inventors: Steven R. Wiley, Raymond G. Goodwin
  • Receptor that binds trail
    Patent number: 7528239
    Abstract: A protein designated TRAIL receptor binds the protein known as TNF-Related Apoptosis-Inducing Ligand (TRAIL). The TRAIL receptor finds use in purifying TRAIL or inhibiting activities thereof. Isolated DNA sequences encoding TRAIL-R polypeptides are provided, along with expression vectors containing the DNA sequences, and host cells transformed with such recombinant expression vectors. Antibodies that are immunoreactive with TRAIL-R are also provided.
    Type: Grant
    Filed: August 20, 1999
    Date of Patent: May 5, 2009
    Assignee: Immunex Corporation
    Inventors: Charles Rauch, Henning Walczak
  • SIGIRR DNA and Polypeptides
    Publication number: 20090111973
    Abstract: DNA encoding SIGIRR polypeptides and methods for using the encoded polypeptides are disclosed.
    Type: Application
    Filed: October 30, 2007
    Publication date: April 30, 2009
    Applicant: IMMUNEX CORPORATION
    Inventor: John Ernest Sims
  • TWEAK receptor
    Patent number: 7517962
    Abstract: The present invention provides the TWEAK receptor and methods for identifying and using agonists and antagonists of the TWEAK receptor. In particular, the invention provides methods of screening for agonists and antagonists and for treating diseases or conditions mediated by angiogenesis, such as solid tumors and vascular deficiencies of cardiac or peripheral tissue.
    Type: Grant
    Filed: June 4, 2004
    Date of Patent: April 14, 2009
    Assignee: Immunex Corporation
    Inventor: Steven R. Wiley
  • Methods of use of the TACI/TACI-L interaction
    Publication number: 20090081700
    Abstract: The invention discloses a novel interaction between a TNF receptor (TACI) and its interacting ligand (TACI-L). Also disclosed are methods of screening candidate molecules to determine potential antagonists and agonists of the TACI/TACI-L interaction. The use of the antagonists and agonists as therapeutics to treat autoimmune diseases, inflammation, and to inhibit graft vs. host rejections is further disclosed.
    Type: Application
    Filed: July 23, 2008
    Publication date: March 26, 2009
    Applicant: Immunex Corporation
    Inventors: Raymond G. Goodwin, Wanwan S. Din